Clinical Trial

Evaluation of the Efficacy of Immunomodulatory Therapy in Case of Psychiatric Disorders With Proven Dysimmunity.

Study acronym: TIM-DePisT
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated July 14, 2023 (before its estimated January 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is an open phase III randomized clinical trial studying the superiority of management by immunomodulator treatment of psychiatric disorders (psychosis and bipolar disorders) for patients previously identified as carriers of autoimmunity such as as the presence of a pathogenic anti-glutamatergic NMDA receptor antibody (NMDAr-Ac).
Trial Details
NCT Number NCT05946486
Lead Sponsor University Hospital, Bordeaux
Conditions Mental Disorder
Enrollment 174 participants
Start Date 2023-10-15
Primary Completion 2026-01-15 (estimated)
Study Completion 2026-12-15 (estimated)
Updated on ClinicalTrials.gov 2023-07-14